Ambrisentan improves exercise capacity in phase 3 trial
Ambrisentan, a propanoic acid type-A selective endothelin receptor antagonist, improved exercise capacity and delayed clinical worsening in patients with pulmonary arterial hypertension (PAH) in phase 3 clinical trial results presented at the annual international conference of the American Thoracic Society in San Diego, Calif.
Ambrisentan, a propanoic acid type-A selective endothelin receptor antagonist, improved exercise capacity and delayed clinical worsening in patients with pulmonary arterial hypertension (PAH) in phase 3 clinical trial results presented at the annual international conference of the American Thoracic Society in San Diego, Calif.
The trial included 192 patients, 65% with idiopathic PAH and 35% with PAH due to connective tissue disease, anorexigen use, or human immunodeficiency virus (HIV). The mean baseline 6-minute walk distance (6MWD) was 348 meters, and 46% of patients were World Health Organization (WHO) functional class 1 or 2 with the remaining patients being functional class 3 or 4.
Patients were randomized to receive 2.5 or 5 mg ambrisentan once daily or placebo for 12 weeks. The primary end point was placebo-corrected 6MWD, and secondary end points were time to clinical worsening and change in WHO functional class, the Borg Dyspnea Index, and results of the SF-36 health survey.
Deterioration in functional class occurred in 18% of placebo patients, 5% of the patients in the 2.5-mg group, and 3% of the patients in the 5-mg group.
Ambrisentan was well tolerated in the trial, with the most frequent adverse event-headache-occurring in 7.8% of those in the 2.5-mg group and 12.7% of those in the 5-mg group, compared with 6.2% in the placebo group.
Remote Care Advancement for Heart Failure, COPD and Diabetes Patients
February 24th 2021In this week's episode of Tuning In to the C-Suite podcast, MHE's Briana Contreras spoke with Dr. Rob Kowal, chief medical officer of the Cardiac Rhythm and Heart Failure division at Medtronic. The two discussed how remote monitoring and IoT is changing healthcare and how remote technology is also gaining a wide-spread adoption to monitor patients at home who have chronic conditions like heart failure, chronic obstructive pulmonary disease and diabetes.
Listen
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
